Skip to main content
PRTA
NASDAQ Life Sciences

Prothena Reports Strong Q1 Net Income Driven by $50M Coramitug Milestone, Advances Key Clinical Programs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$10.53
Mkt Cap
$566.323M
52W Low
$4.32
52W High
$11.69
52W Position info
144% above low
Off High info
9.9% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

PRTA has more than doubled off its 52-week low of $4.32.

Summary

Prothena reported a net income of $32.7 million in Q1 2026, a significant reversal from a prior-year loss, fueled by a $50 million milestone payment for its Coramitug program and positive operating cash flow, alongside continued advancement of its clinical pipeline.


Key Events · Earnings and Guidance · PRTA

  • Achieved Q1 Net Income of $32.7 Million

    The company reported a net income of $32.7 million for the three months ended March 31, 2026, a substantial improvement from a net loss of $60.2 million in the same period last year.

  • Received $50 Million Coramitug Milestone Payment

    Revenue was significantly boosted by a $50 million development milestone payment from Novo Nordisk related to the advancement of coramitug in its Phase 3 CLEOPATTRA clinical trial.

  • Generated Positive Operating Cash Flow

    Net cash provided by operating activities was $28.9 million for Q1 2026, a strong turnaround from $53.4 million used in operating activities in Q1 2025.

  • Advanced Multiple Clinical Programs

    Key pipeline updates include the initiation of Phase 3 trials for Prasinezumab (Parkinson's) and Coramitug (ATTR amyloidosis), and Fast Track designations for Coramitug and BMS-986446 (Alzheimer's).


Analysis · PRTA · Life Sciences

Prothena has reported a significant financial turnaround in Q1 2026, moving from a substantial net loss in the prior year to a net income of $32.7 million. This positive shift was primarily driven by a $50 million development milestone payment from Novo Nordisk for the continued advancement of coramitug in its Phase 3 clinical trial. The company also demonstrated a strong improvement in operational efficiency, generating $28.9 million in cash from operations compared to a significant cash burn in the prior year. This financial strength, coupled with ongoing progress in multiple late-stage clinical programs and a continued share repurchase program, signals robust operational execution and a positive outlook for investors.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRTA was trading at $10.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $566.3M. The 52-week trading range was $4.32 to $11.69. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRTA - Latest Insights

PRTA
Nov 05, 2026, 5:55 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $8.20 info
Change: +$0.310 (+4%) info
Market Cap: $422.095M info
PRTA
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.89
Real-time Price: $8.20 info
Change: +$0.310 (+4%) info
Market Cap: $422.095M info
PRTA
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.88
Real-time Price: $8.20 info
Change: -$0.680 (-8%) info
Market Cap: $422.095M info
PRTA
Aug 06, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.58
Real-time Price: $8.20 info
Change: -$0.380 (-4%) info
Market Cap: $422.095M info
PRTA
Aug 06, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.58
Real-time Price: $8.20 info
Change: -$0.380 (-4%) info
Market Cap: $422.095M info